Reply: SUN vs BEV\+IFN in first-line mRCC therapy: No evidence for a statistically significant difference in progression-free survival

dc.contributor.author	Thompson-Coon, Jo
dc.contributor.author	Liu, Z
dc.contributor.author	Hoyle, M
dc.contributor.author	Rogers, G
dc.contributor.author	Green, C
dc.contributor.author	Moxham, T
dc.contributor.author	Welch, K
dc.contributor.author	Stein, Ken
dc.date.accessioned	2015-08-06T09:46:07Z
dc.date.issued	2010-01-05
dc.description.abstract	Letter to the Editor	en_GB
dc.identifier.citation	Vol. 102, Issue 1, pp. 234 - 235	en_GB
dc.identifier.doi	10.1038/sj.bjc.6605447
dc.identifier.uri	http://hdl.handle.net/10871/18005
dc.language.iso	en	en_GB
dc.publisher	Cancer Research UK / Nature Publishing Group	en_GB
dc.relation.url	http://www.nature.com/bjc/journal/v102/n1/full/6605447a.html	en_GB
dc.rights	This work is licensed under the Creative Commons Attribution-NonCommercial-Share Alike 3.0 Unported License. To view a copy of this license, visit http://creativecommons.org/licenses/by-nc-sa/3.0/	en_GB
dc.title	Reply: SUN vs BEV\+IFN in first-line mRCC therapy: No evidence for a statistically significant difference in progression-free survival	en_GB
dc.type	Article	en_GB
dc.date.available	2015-08-06T09:46:07Z
dc.identifier.issn	0007-0920
dc.description	Copyright © 2015 Cancer Research UK	en_GB
dc.description	This is an BJC Open article	en_GB
dc.identifier.journal	British Journal of Cancer	en_GB